Screener
Ardelyx ARDX Product sales, net — Concentration risk (as percent)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.
The source filing: Ardelyx’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437402-26-000044
| (in thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product sales, net | ||||
| IBSRELA | $86,243 | $65,045 | $156,317 | $109,448 |
| XPHOZAH | 31,886 | 25,032 | 55,185 | 48,443 |
| Total product sales, net | $118,129 | $90,077 | $211,502 | $157,891 |
| Product sales, net as a percentage of total revenues | 97.7% | 92.2% | 98.2% | 91.9% |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ardelyx's product sales, net — concentration risk (as percent)?
- Ardelyx (ARDX) reported product sales, net — concentration risk (as percent) of 97.7% in Q2 2026.
- How has Ardelyx's product sales, net — concentration risk (as percent) changed year-over-year?
- Ardelyx's product sales, net — concentration risk (as percent) increased by 6.0% year-over-year, from 92.2% to 97.7%.
- What does product sales, net — concentration risk (as percent) mean?
- This metric measures the degree to which total product revenue is dependent on a limited number of customers, distributors, or specific therapeutic indications. A high concentration indicates significant exposure to the purchasing behavior or regulatory status of a small group of entities. Monitoring this helps investors evaluate the stability of revenue streams and the potential impact of losing key commercial relationships.
Ask your AI about Ardelyx's product sales, net — concentration risk (as percent).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude